Table 3 Factors associated with the occurrence of cardiovascular events
From: Cardiovascular disease events within 5 years after a diagnosis of breast cancer
N = 682 | Modality | No Event | Event |
|---|---|---|---|
HER2 overexpression (N = 682) | Y | 551 (85%) | 25 (73.5%) |
N | 69 (10.6%) | 9 (26.5%) | |
NA | 28 (4.3%) | 0 (0%) | |
Left breast (N = 682) | Y | 340 (52.5%) | 17 (50%) |
N | 308 (47.5%) | 17 (50%) | |
NA | 0 (0%) | 0 (0%) | |
Triple negative status (N = 682) | N | 590 (91%) | 32 (94.1%) |
Y | 56 (8.6%) | 2 (5.9%) | |
NA | 2 (0.3%) | 0 (0%) | |
Metastatic at diagnosis (N = 682) | Inf IV | 634 (97.8%) | 33 (97.1%) |
IV | 14 (2.2%) | 1 (2.9%) | |
NA | 0 (0%) | 0 (0%) | |
UICC (N = 682) | <III | 573 (88.4%) | 19 (55.9%) |
> = III | 75 (11.6%) | 15 (44.1%) | |
NA | 0 (0%) | 0 (0%) | |
Chemotherapy with anthracyclines (N = 682) | Y | 162 (25%) | 12 (35.3%) |
N | 73 (11.3%) | 9 (26.5%) | |
NA | 413 (63.7%) | 13 (38.2%) | |
Hormonotherapy (N = 682) | Y | 525 (81%) | 26 (76.5%) |
N | 123 (19%) | 8 (23.5%) | |
NA | 0 (0%) | 0 (0%) | |
Pre-existing cardiovascular disease risk factors (N = 682) | N | 332 (51.2%) | 9 (26.5%) |
Y | 315 (48.6%) | 25 (73.5%) | |
NA | 1 (0.2%) | 0 (0%) |